Company Filing History:
Years Active: 2021
Title: Peter Bold - Innovator in Pharmaceutical Chemistry
Introduction
Peter Bold is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit specific biological pathways. His work is essential in advancing therapeutic options for various medical conditions.
Latest Patents
Peter Bold holds a patent for the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one. This compound acts as a phosphatidylinositol 3-kinase inhibitor, which is crucial for regulating cellular functions. The patent also covers pharmaceutically acceptable salts and compositions that utilize this compound to inhibit phosphatidylinositol 3-kinase (PI3K) activity.
Career Highlights
Peter Bold is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His role involves research and development of innovative therapeutic solutions. His expertise in pharmaceutical chemistry has been instrumental in the advancement of new drug candidates.
Collaborations
Peter has collaborated with notable colleagues, including Matthew Wd Perry and Christian Tyrchan. These collaborations have fostered a productive environment for innovation and have contributed to the success of their projects.
Conclusion
Peter Bold is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in drug development. His contributions, particularly in the area of PI3K inhibitors, highlight the importance of innovation in addressing medical challenges.